GenScript Biotech Corporation · HKEX:1548
GenScript Biotech — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
33 slides from GenScript Biotech's conference presentation, Jan 10, 2024
Slide 1: Voluntary Announcement: Presentations on Company Updates at 42nd J.P. Morgan Healthcare Conference
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia
Slide 2: Hong Kong, 10 January 2024
Hong Kong, 10 January 2024 As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo H
Slide 3: GenScript Biotech Corporation
HK. 1548 GenScript Biotech Corporation Make People and Nature Healthier through Biotechnology
Slide 4: Disclaimer
Disclaimer* Forward-Looking Statement This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although
Slide 5: Content
Content Company Overview Pioneering in Cell and Gene Therapy From DNA to Synthetic Biology Key Investment Highlights GenScript Employee Photography
Slide 6: Mission
Mission Make People and Nature Healthier through Biotechnology 2002 2014 2018 2023 Founded in New Jersey, US Founded Legend Biotech Established Biologics CRISPR GMP Facility CDMO Segment Launched (Cell Therapy Segment) (GenScript ProBio) 2013 2015 2022 Established Bestzyme GenScript was listed on HK
Slide 7: Financial Snapshot
Financial Snapshot Group Revenue ($M) CARVYKTI® Sales ($M) 391 18 309 17 65 626 60 152 110 Industrial Synthetic Biology 62 117 Biologics CDMO 72 170 199 Cell Therapy 55 55 Life Science 24 FY 19 FY 20 FY 21 FY 22 1H2022 1H2023 22Q2 22Q3 22Q4 23Q1 23Q2 23Q3 • Two decades of sustained • Leading gene sy
Slide 8: Global Footprint
Global Footprint1 Research and manufacturing sites Regional offices and logistics centers ~6,500 Global employees Netherlands Korea United Kingdom ~800 R&D team Belgium Ireland Japan ~40% Master's degree or higher Seattle, Washington, USA Jiangsu, Shandong, Shanghai, China in 100+ countries and regi
Slide 9: Pioneering in Cell and Gene Therapy
Pioneering in Cell and Gene Therapy Customized Research Clinical Manufacturing Unmet Medical Needs 7
Slide 10: Global Leading Gene Synthesis Provider
Global Leading Gene Synthesis Provider 20 Years + 200,000+ 3,000,000+ of experience customers from over 100 synthetic genes countries delivered Automated Gene Synthesis Platform Efficient Plasmid Extraction Platform • Efficiency doubled compared to manual1 • 100% full insert sequence accuracy-AAV IT
Slide 11: Supporting CRISPR Genomic Medicines
Supporting CRISPR Genomic Medicines* 100+ Batches 20+ 30 6 successful audits IND projects IND approvals GMP products Services Facility • ~421,000 sq.ft Synthetic CRISPR sgRNA HDR Knock-in Templates Cas Nucleases • GMP grade • GMP grade • GMP grade • 17 manufacturing lines • From mg to grams • From m
Slide 12: Leading Plasmid CDMO
Leading Plasmid CDMO 10 1. As of Nov.2023
Slide 13: Global CGT GMP MFG Capacity
Global CGT GMP MFG Capacity • State-of-the-art plasmid facility with Plasmid PD Lab (In Service) 220,000 sq.ft • 1L-10L plasmid production • Total 16 GMPro™ and GMP plasmid manufacturing lines • Has both single-use and stainless Integrated Plasmid Facility (In Service) steel systems, from 5L to 500L
Slide 14: Cilta-cel: Potential Best-in-Class Clinical Profile
Cilta-cel: Potential Best-in-Class Clinical Profile 1L CARTITUDE-5 (1L MM, transplant not intended): enrollment to be completed by 1H 2024 ~160k pts 1 , 2 CARTITUDE-6 (1L MM, transplant eligible): enrollment began in 2H 2023 Potential to be a new SoC CARTITUDE-4: Cilta-cel vs SOC 2~4L ∙ 12-month PFS
Slide 15: CARVYKTI Commercialization and Manufacturing Capabilities
CARVYKTI® Commercialization and Manufacturing Capabilities State-Of-The-Art CARVYKTI® Manufacturing Facilities • Obelisc Facility in Ghent, Belgium received license from the Federal Agency for Medicines and Health Products in Belgium for clinical supply manufacturing • Awaiting Investigational Medic
Slide 16: From DNA to Synthetic Biology
From DNA to Synthetic Biology Enabling Tools Integrated Systems Enabled Products 14
Slide 17: Exploring More Possibilities in SynBio Frontier
Exploring More Possibilities in SynBio Frontier Healthcare Consumer Products Protein Engineering • Medical devices • Textile products • Advanced Gene Editing Technologies-CRISPR/Cas9 to • Medicinal ingredients • Cosmetics • Advanced therapy • Pet food edit multiple genes simultaneously • Household •
Slide 18: Key Investment Highlights
Key Investment Highlights 01 • • A $10B+ addressable market 20 years of consecutive growth 03 • Unique offering of plasmid and virus vector in CGT applications • Growing with research communities by • Incoming U.S. plasmid manufacturing Life providing innovative life science services and Biologics f
Slide 19: Thanks
HK. 1548 GenScript Biotech Corporation Make People and Nature Healthier through Biotechnology Thanks For More Information: https://www.genscript.com/
Slide 20: Legend Biotech Corporate Presentation
Legend Biotech Corporate Presentation J A N U A RY 2 0 2 4 1 This presentation is for investor relations purposes only – Not for product promotional purposes
Slide 21: Disclaimer
Disclaimer This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in th
Slide 22: Legend Biotech Highlights
Legend Biotech Highlights Years Since Inception One of the earliest companies Employees Marketed Product: Pipeline Programs Covering: to engineer CAR-T cells for the CARVYKTI® Hematologic malignancies BCMA protein Dedicated to R&D (ciltacabtagene Solid tumors autoleucel; cilta-cel)1,2 Core Techn
Slide 23: CARVYKTI Uptake Continues
CARVYKTI® Uptake Continues Continued market penetration, geographic expansion, and population in earlier lines of treatment represent significant growth drivers and opportunity Q3’23 OVER CARVYKTI® Net Product Sales ($MM) YOY GROWTH Q2’23 GROWTH +176% growth vs Q3’22 U.S. 155% 23% 160 EU N/A 300% 14
Slide 24: A New Standard for CAR-T Launches
A New Standard for CAR-T Launches CARVYKTI® - INDUSTRY FIRST SIX QUARTERS L E A D I N G E A R LY L A U N C H OUTPERFORMING HISTORICAL PERFORMANCE CAR-T LAUNCHES WORLDWIDE SALES OF CAR -T THERAPIES, BY QUARTER OF LAUNCH (IN $MM) 400 391 Kymriah Yescarta Tecartus Breyanzi Abecma Carvykti 350 300 Quart
Slide 25: Pioneer and Leader in Cell Therapy
Pioneer and Leader in Cell Therapy 6 This presentation is for investor relations purposes only – Not for product promotional purposes
Slide 26: A Fully Integrated Global Leader in Cell Therapy
A Fully Integrated Global Leader in Cell Therapy MARKET-LEADING MULTIPLE MYELOMA (MM) CAR-T THERAPY • sBLA and Type II variation to support label expansion accepted by U.S. FDA (PDUFA target action date of April 5, 2024) and EMA, respectively • Application supported by first randomized Phase 3 study
Slide 27: Our Differentiated R&D Approach
Our Differentiated R&D Approach Potential best-in-class proprietary technology platforms and end-to-end capability Armoring Antibody Diverse platform strategy for screening for allogeneic solid tumors & engineering treatments Multiple armored CAR-T In-house antibody Diverse allogeneic strategies to
Slide 28: Legend and J&J Global Collaboration
Legend and J&J Global Collaboration Worldwide collaboration and license agreement to develop and commercialize cilta-cel Europe 50/50 United States 50/50 50/50 50/50 Japan 70/30 Greater China Upfront Payment Second Milestone Fourth Milestone Sixth Milestone 9th Milestone Eligible for Potential $25 m
Slide 29: Global Manufacturing Footprint
Global Manufacturing Footprint US Facilities EU Facilities China Facilities Raritan, NJ Ghent, Belgium Nanjing Future Commercial Site for Legend China Clinical Supply Site for US / EU / JP / ROW Launch/ Pipeline Programs & Potential China Commercial Site for CARVYKTI® CARVYKTI® Launch Site for CARVY
Slide 30: Expanding Our Manufacturing Capabilities
Expanding Our Manufacturing Capabilities Bringing cell therapies to market given unique challenges to improve overall supply State-Of-The-Art CARVYKTI® Manufacturing Facilities • Obelisc Facility in Ghent, Belgium received license from the Federal Agency for Medicines and Health Products in Belgium
Slide 31: Out-licensing Deal with Novartis on CAR-T Therapies Targeting DLL3
Out-licensing Deal with Novartis on CAR-T Therapies Targeting DLL3 • Legend announced on Nov 13, 2023 an exclusive, global license agreement with Novartis to advance certain DLL3-targeted CAR-T therapies, including LB2102, an investigational therapy for small cell lung cancer. • Legend announced on
Slide 32: Our Pipeline
Our Pipeline Global US China PRECLINICAL PHASE 1 PHASE 2 PHASE 3 SCLC‡§ RRMM (BCMA)* NSCLC (DLL3) RRMM (BCMA) HCC† RRMM (BCMA)* 1-3 Prior Lines (GPC3) LEGEND-2† (GPC3) CARTIFAN-1 Autologous CARTITUDE-4 Autologous Autologous Autologous Autologous Autologous NCT05680922 NCT03090659 NCT05352542 NCT0375
Slide 33: Outlook: 2024 and Beyond
Outlook: 2024 and Beyond NEAR-TERM GOALS LONG-TERM GROWTH STRATEGY → Continue to increase manufacturing capacity and → Move CARVYKTI® to earlier lines of therapy; increase efficiency penetration in the US and expand into global markets → Begin manufacturing from Ghent facilities → Focus on unmet med
GenScript Biotech — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix